RxDoctor Payments DataLook up a doctor →

Carly Piel, PA

Physician Assistant · Bryn Mawr, PANPI 1194366823

Payments from drug & device makers

$43,537in general payments, 2019–2025

Across 630 payments — averaging $69.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$19K
  • Janssen Scientific Affairs, LLC$7K
  • Bayer$3K
  • Pfizer$2K
  • Astellas Pharma US Inc$2K
  • Teleflex LLC$1K
  • plus $8K from 42 others

What the payments were for

  • Consulting fees$23,73555%
  • Speaking & faculty fees$3601%
  • Travel & lodging$2271%
  • Food & beverage$17,97641%
  • Education$1,2393%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,537 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$141,373
Medicare patients
538
Services billed
12,575

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide17$173,999
MyrbetriqMirabegron203$134,135
GemtesaVibegron150$110,090
OrgovyxRelugolix42$109,576
Abiraterone Acetate16$81,731
JatenzoTestosterone Undecanoate11$11,235
Tamsulosin Hcl628$11,228
Methenamine Hippurate101$8,287
Silodosin59$4,969
Finasteride153$2,769
Estradiol41$2,664
Potassium Citrate ErPotassium Citrate23$2,203
CefuroximeCefuroxime Axetil199$2,199
Oxybutynin Chloride ErOxybutynin Chloride77$1,802
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst140$1,587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$2,413$308,134220 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$490$219,666192 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$7,479$81,73116 claims
Clarus Therapeutics Inc.Jatenzo$44$11,23511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Bryn Mawr

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →